Investigating the primary target and mechanism-of-action of 2-MMB for the treatment of LQTS

Long QT Syndrome (LQTS) is a genetic disorder that causes prolongation of cardiac repolarization, observed as an elongation between the Q and T waves observed on an electrocardiogram. The lengthening of these waves can cause unexpected and life threatening arrhythmias. Current therapies for the LQTS are limited to ?-blockers and left cardiac sympathetic denervation which prevent fatal arrhythmia and Implantable Cardiac-Defibrillators (ICD) which terminate arrhythmia. However, these therapies often need to be used in combination, and impact negatively the quality of life of the patients. So far, no therapy actually restores normal repolarization and shortens the QT interval. Recently a compound, 2-MMB, has been reported to rescue LQTS on zebrafishes by correcting the repolarization defect. However, no therapeutic target has been identified yet for this compound, and the mechanism of action remains unknown. The purpose of that project is to identify the therapeutic target of 2-MMB.

Faculty Supervisor:

Andreea Schmitzer

Student:

Partner:

Thryv Therapeutics

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Biotechnology; Pharmaceuticals

University:

Université de Montréal

Program: